Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates news across four distinct healthcare sectors: medical devices, diagnostics, nutrition, and pharmaceuticals. This diversification produces a steady flow of announcements spanning FDA approvals for cardiac devices and diabetes technology, clinical trial results, product launches, and quarterly earnings reports.
Abbott's medical devices business drives significant news volume through regulatory clearances for cardiovascular implants, continuous glucose monitoring innovations, and structural heart interventions. The FreeStyle Libre platform and cardiac rhythm management portfolio generate regular updates on expanded indications, international approvals, and clinical evidence supporting device efficacy.
Quarterly earnings releases reveal segment-by-segment performance across Abbott's four divisions, providing insight into medical device adoption rates, diagnostic testing volumes, nutrition product demand, and emerging market pharmaceutical sales. As a Dividend Aristocrat with more than five decades of consecutive dividend increases, Abbott's dividend announcements attract income-focused investor attention.
Product development news includes CE Mark approvals for European markets, FDA 510(k) clearances, breakthrough device designations, and clinical study enrollments. Abbott's global manufacturing footprint and commercial presence in over 160 countries means regulatory and market access news spans multiple geographic regions.
Bookmark this page to follow Abbott's medical device innovations, diagnostic technology advancements, nutrition product developments, and financial performance updates as they are announced.
Abbott and the Big Ten Conference's 'We Give Blood Drive' competition saw nearly 20,000 participants donate blood across the country, potentially saving up to 60,000 lives. The University of Nebraska-Lincoln won the competition, receiving a $1 million grant from Abbott to advance student and community health.
The initiative aimed to address one of the biggest blood shortages in a generation, particularly noting the decline in donors aged 19-24 by nearly a third in recent years. More than half of the campus blood drive donors were first-time contributors. The competition ran from September 26 through December 6 and will return next football season.
Abbott (NYSE: ABT) announced its first patient procedures using an investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating severe aortic stenosis. This system represents the initial phase toward developing a software-guided TAVI system with AI capabilities. The technology will complement Abbott's existing Navitor™ TAVI system, offering physicians additional options for patient treatment.
The balloon-expandable device works by crimping a new heart valve on a deflated balloon, which is inserted through a leg artery and guided to the heart. The balloon is then inflated to expand the valve, replacing the function of the narrowed native valve.
Tidepool has announced a new cloud-to-cloud data integration partnership with Abbott (NYSE: ABT) for continuous glucose monitoring (CGM). The integration will enable automatic data streaming from Abbott's FreeStyle Libre CGM devices to Tidepool+, a diabetes data visualization and population health platform. This partnership allows healthcare providers to initiate connections with patients using FreeStyle Libre 1, 2, and 3 devices, both in-clinic and remotely. The integration aims to streamline diabetes care workflows and provide comprehensive patient data overview through Tidepool's Population Health Dashboard.
Tidepool announces a new cloud-to-cloud data integration partnership with Abbott's FreeStyle Libre portfolio of continuous glucose monitoring (CGM) systems in the U.S. This integration will enable automatic data streaming from Abbott's CGMs to Tidepool+, a diabetes data visualization and population health platform. The collaboration aims to streamline diabetes care workflows and expand patient choice.
The integration will allow clinics and health systems using Tidepool+ to establish connections with patients using FreeStyle Libre 2 and 3 systems, either in-clinic or remotely. The platform will merge data from FreeStyle Libre sensors into its Population Health Dashboard, providing clinicians with comprehensive patient outcome assessments.
Tidepool announces a new cloud-to-cloud data integration with Abbott's FreeStyle Libre portfolio of continuous glucose monitoring (CGM) systems in the U.S. The integration will enable automatic data streaming from FreeStyle Libre 2 and 3 systems to Tidepool+, a diabetes data visualization and population health platform. This collaboration aims to streamline diabetes care workflows and provide better access to device data through interoperable solutions. Healthcare providers will be able to initiate connections with patients either in clinic or remotely, creating a comprehensive overview of patient outcomes through the Population Health Dashboard.
Abbott (NYSE: ABT) announced the launch of TEAM-HF, a groundbreaking clinical trial aimed at improving outcomes for advanced heart failure patients. The study will enroll up to 850 patients across 75 sites worldwide, using Abbott's CardioMEMS™ HF System to monitor pulmonary artery pressures and identify patients who could benefit from early HeartMate 3™ left ventricular assist device intervention. The trial addresses a critical gap in heart failure treatment, as approximately 6.7 million Americans have heart failure, with numbers expected to reach 8.5 million by 2030. The study's primary and secondary endpoints will be evaluated at two years, with follow-up through five years.
Abbott (NYSE:ABT) and the Big Ten Conference have launched 'The We Give Blood Drive,' a first-ever conference-wide blood donation competition. Running from Sept. 26 through Dec. 6, the initiative aims to address critical U.S. blood shortages by engaging 18 member schools' students, alumni, and fans. The school generating the most donations will receive a $1 million grant for student or community health, announced at the Big Ten Championship Game on Dec. 7. Participants receive a free one-month B1G+ streaming subscription and entry to win championship game tickets. The competition addresses declining younger donor numbers and aims to ensure a stable blood supply.
Abbott and Abbott Fund are responding to the devastation caused by Hurricanes Helene and Milton in the southeastern United States. Working with disaster relief partners like Feeding America, Direct Relief, Americares, and World Central Kitchen, they're providing aid to affected communities in Florida, Georgia, North Carolina, and Tennessee.
The company's proactive approach included pre-positioning 'disaster relief packs' with nutrition and medical products at food banks and health clinics. Additional donations of Ensure, PediaSure, Glucerna, Pedialyte, Similac, and diabetes care products have been made to meet immediate needs. Abbott Fund is also providing grants to support basic necessities and medical care in the aftermath of Hurricane Milton.
Abbott reported third-quarter 2024 results with sales of $10.6 billion, driven by strong underlying base business performance. Reported sales growth was 4.9%, with organic sales growth for the underlying base business at 8.2%, led by double-digit growth in Medical Devices. Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales. The company raised its full-year adjusted diluted EPS guidance to $4.64 to $4.70. Abbott's board authorized a new $7 billion share repurchase program. Notable developments include a partnership with Medtronic for continuous glucose monitoring, the U.S. launch of Lingo™, and completion of enrollment in the VOLT-AF IDE trial for the Volt™ Pulsed Field Ablation System.
Abbott (NYSE: ABT) announced significant progress in its pulsed field ablation (PFA) solutions for electrophysiology. The company completed enrollment ahead of schedule in the VOLT-AF IDE Study for the Volt™ PFA System and launched the global FOCALFLEX trial for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™. These studies advance two Abbott PFA catheters for treating atrial fibrillation (AFib).
Additionally, Abbott received FDA clearance for the Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, supporting mapping of PFA and radiofrequency ablation cases. The Volt PFA System pairs a balloon-in-basket catheter with Abbott's EnSite™ X EP System for improved heart mapping. The TactiFlex Duo Ablation Catheter offers both PFA and RF energy delivery with a flexible tip for precise targeting.
These advancements aim to overcome limitations of early-generation PFA systems and provide physicians with more options for treating AFib patients.
FAQ
What is the current stock price of Abbott Labs (ABT)?
What is the market cap of Abbott Labs (ABT)?
